Following mapping of the prenatal development of the serotonergic system [5] , we were able to examine the relationship of developing 5-HT nerve terminals to their embryonic target cells and reassess data from our previous p CPA study [6] . This analysis, together with a subsequent study [7] , showed a strong correlation between the spatiotemporal distribution of developing 5-HT axons, inhibition of 5-HT synthesis within these cells [7] , and delayed onset of neuronal differentiation in specific regions of the embryonic rat brain [6] .
We undertook this study [1] because we had found that serotonin (5-HT) as well as norepinephrine and dopamine neurons were born several days prior to those cells they will eventually innervate [2] . We chose to pharmacologically manipulate the developing seroteonergic system in the embryo because of the availability of a drug, p -chlorophenylanaline ( p CPA) that biochemically inhibited 5-HT synthesis [3] , rather than destroying nerve terminals, as with 6-OH-dopamine [4] . This paper was highly cited because it provided the first evidence that 5-HT regulates differentiation of its target cells in the developing brain. This was based on the finding that treatment of pregnant rats with p CPA beginning on embryonic day 8, delayed the onset of differentiation (day of last precursor cell division) of neurons innervated by 5-HT nerve terminals in the adult brain (5-HT target cells) [1] . However, it was not known whether embryonic target cells of developing 5-HT neurons were similarly affected.
